Deoxyuridine analog nucleotides in deoxycytidine analog treatment: Secondary active metabolites?

Fundamental and Clinical Pharmacology

Volumn 25, Issue 2, 2011, Pages 172-185

  Jansen, Robert S ^a   Rosing, Hilde ^a   Schellens, Jan H M ^a,b   Beijnen, Jos H ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Cytidine deaminase; Deoxycytidine analogs; Deoxycytidine monophosphate deaminase; Deoxyuridine nucleotides; Intracellular pharmacology

Indexed keywords

2' DEOXY 2' FLUORO 2' METHYLCYTIDINE; 5 AZA 2' DEOXYCYTIDINE; ADENOSINE DEAMINASE INHIBITOR; CAPECITABINE; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; DEOXYURIDINE DERIVATIVE; DEOXYURIDINE TRIPHOSPHATE DERIVATIVE; EMTRICITABINE; FLUCYTOSINE DEOXYRIBOSIDE; FLUOROURACIL; GEMCITABINE; MONOPHOSPHATE DERIVATIVE; NUCLEIC ACID; PHOSPHATE; PRODRUG; RO 2433 TP; TETRAHYDROURIDINE; THYMIDYLATE SYNTHASE; TORCITABINE; UNCLASSIFIED DRUG; URIDINE ANALOG MONOPHOSPHATE DERIVATIVE; URIDINE ANALOG TRIPHOSPHATE DERIVATIVE; ZEBULARINE;

AREA UNDER THE CURVE; CHEMICAL INTERACTION; DEAMINATION; DRUG ACTIVITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; METABOLITE; NONHUMAN; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; DCMP DEAMINASE; DEAMINATION; DEOXYCYTIDINE; DEOXYURACIL NUCLEOTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHOSPHORYLATION;

EID: 79952401706     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2010.00823.x     Document Type: Review

References (91)

1. Matsuda A., Sasaki T. Antitumor activity of sugar-modified cytosine nucleosides. Cancer Sci. (2004) 95 105-111.
2. Jordheim L., Galmarini C.M., Dumontet C. Drug resistance to cytotoxic nucleoside analogues. Curr. Drug Targets. (2003) 4 443-460.
3. Bergman A.M., Pinedo H.M., Peters G.J. Determinants of resistance to 2', 2'-difluorodeoxycytidine (gemcitabine). Drug Resist. Updat. (2002) 5 19-33.
4. Newman E.M., Santi D.V. Metabolism and mechanism of action of 5-fluorodeoxycytidine. Proc. Natl. Acad. Sci. U S A (1982) 79 6419-6423.
5. Murakami E., Niu C., Bao H. et al. The mechanism of action of beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine involves a second metabolic pathway leading to beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine 5'-triphosphate, a potent inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob. Agents Chemother. (2008) 52 458-464.
6. Veltkamp S.A., Pluim D., van Eijndhoven M.A. et al. New insights into the pharmacology and cytotoxicity of gemcitabine and 2', 2'-difluorodeoxyuridine. Mol. Cancer Ther. (2008) 7 2415-2425.
7. Ma H., Jiang W.R., Robledo N. et al. Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species. J. Biol. Chem. (2007) 282 29812-29820.
8. Hamada A., Kawaguchi T., Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin. Pharmacokinet. (2002) 41 705-718.
9. Schrecker A.W., Urshel M.J. Metabolism of 1-beta-D-Arabinofuranosylcytosine in Leukemia L1210: studies with Intact Cells. Cancer Res. (1968) 28 793-801.
10. Chou T.C., Arlin Z., Clarkson B.D., Phillips F.S. Metabolism of 1-beta-D-arabinofuranosylcytosine in human leukemic cells. Cancer Res. (1977) 37 3561-3570.
11. Jamieson G.P., Finch L.R., Snook M., Wiley J.S. Degradation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human leukemic myeloblasts and lymphoblasts. Cancer Res. (1987) 47 3130-3135.
12. Wiley J.S., Taupin J., Jamieson G.P., Snook M., Sawyer W.H., Finch L.R. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J. Clin. Invest. (1985) 75 632-642.
13. Braess J., Pfortner J., Kaufmann C.C. et al. Detection and determination of the major metabolites of [3H]cytosine arabinoside by high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl. (1996) 676 131-140.
14. Gandhi V., Xu Y.Z., Estey E. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia. Clin. Cancer Res. (1998) 4 1719-1726.
15. Heinemann V., Hertel L.W., Grindey G.B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2', 2'-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. (1988) 48 4024-4031.
16. Heinemann V., Xu Y.Z., Chubb S. et al. Cellular elimination of 2', 2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation. Cancer Res. (1992) 52 533-539.
17. Veltkamp S.A., Jansen R.S., Callies S. et al. Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study. Clin. Cancer Res. (2008) 14 3477-3486.
18. Veltkamp S.A., Pluim D., van Tellingen O., Beijnen J.H., Schellens J.H. Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice. Drug Metab. Dispos. (2008) 36 1606-1615.
19. Stuyver L.J., McBrayer T.R., Tharnish P.M. et al. Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir. Chem. Chemother. (2006) 17 79-87.
20. Asif G., Hurwitz S.J., Shi J., Hernandez-Santiago B.I., Schinazi R.F. Pharmacokinetics of the antiviral agent beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine in rhesus monkeys. Antimicrob. Agents Chemother. (2007) 51 2877-2882.
21. Bryant M.L., Bridges E.G., Placidi L. et al. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. (2001) 45 229-235.
22. Standring D.N., Bridges E.G., Placidi L. et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir. Chem. Chemother. (2001) 12(Suppl. 1) 119-129.
23. Hernandez-Santiago B., Placidi L., Cretton-Scott E. et al. Pharmacology of beta-L-thymidine and beta-L-2'-deoxycytidine in HepG2 cells and primary human hepatocytes: relevance to chemotherapeutic efficacy against hepatitis B virus. Antimicrob. Agents Chemother. (2002) 46 1728-1733.
24. Mukherjee K., Heidelberger C. Studies of fluorinated pyrimidines. XV. Inhibition of the incorporation of formate-C14 into DNA thymine of Ehrlich ascites carcinoma cells by 5-fluoro-2'-deoxyuridine-5'-monophosphate and related compounds. Cancer Res. (1962) 22 815-822.
25. Mekras J.A., Boothman D.A., Perez L.M., Greer S. Use of 5-fluorodeoxycytidine and tetrahydrouridine to exploit high levels of deoxycytidylate deaminase in tumors to achieve DNA- and target-directed therapies. Cancer Res. (1984) 44 2551-2560.
26. Boothman D.A., Briggle T.V., Greer S. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma. Cancer Res. (1987) 47 2354-2362.
27. Beumer J.H., Eiseman J.L., Parise R.A. et al. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice. Clin. Cancer Res. (2006) 12 7483-7491.
28. Boothman D.A., Briggle T.V., Greer S. Metabolic channeling of 5-fluoro-2'-deoxycytidine utilizing inhibitors of its deamination in cell culture. Mol. Pharmacol. (1985) 27 584-594.
29. Momparler R.L. Pharmacology of 5-Aza-2'-deoxycytidine (decitabine). Semin. Hematol. (2005) 42 S9-16.
30. Cihak A. Transformation of 5-aza-2'-deoxycytidine-3H and its incorporation in different systems of rapidly proliferating cells. Eur. J. Cancer (1978) 14 117-124.
31. Grant S., Rauscher F. III, Margolin J., Cadman E. Dose- and schedule-dependent activation and drug synergism between thymidine and 5-aza-2'-deoxycytidine in a human promyelocytic leukemia cell line. Cancer Res. (1982) 42 519-524.
32. Hurwitz S.J., Otto M.J., Schinazi R.F. Comparative pharmacokinetics of Racivir, (+/-)-beta-2', 3'-dideoxy-5-fluoro-3'-thiacytidine in rats, rabbits, dogs, monkeys and HIV-infected humans. Antivir. Chem. Chemother. (2005) 16 117-127.
33. Paff M.T., Averett D.R., Prus K.L., Miller W.H., Nelson D.J. Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1, 3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob. Agents Chemother. (1994) 38 1230-1238.
34. Muller W.E.G., Zahn R.K. Metabolism of 1-{beta}-D-Arabinofuranosyluracil in Mouse L5178Y Cells. Cancer Res. (1979) 39 1102-1107.
35. Tiefenthaler M., Hohla F., Irschick E. et al. In vitro studies on the immunosuppressive effect of 2', 2'-difluorodeoxycytidine (dFdC) and its metabolite 2', 2'-difluorodeoxyuridine (dFdU). Immunobiology (2003) 207 149-157.
36. Wang L., Munch-Petersen B., Herrstrom S.A. et al. Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Lett. (1999) 443 170-174.
37. Plunkett W., Gandhi V., Chubb S. et al. 2', 2'-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia Cells. Nucleosides Nucleotides Nucleic Acids (1989) 8 775-785.
38. Heinemann V., Plunkett W. Modulation of deoxynucleotide metabolism by the deoxycytidylate deaminase inhibitor 3, 4, 5, 6-tetrahydrodeoxyuridine. Biochem. Pharmacol. (1989) 38 4115-4121.
39. Barchi J.J. Jr, Cooney D.A., Hao Z. et al. Improved synthesis of zebularine [1-(beta-D-ribofuranosyl)-dihydropyrimidin-2-one] nucleotides as inhibitors of human deoxycytidylate deaminase. J. Enzyme Inhib. (1995) 9 147-162.
40. Momparler R.L., Rossi M., Bouchard J., Vaccaro C., Momparler L.F., Bartolucci S. Kinetic interaction of 5-AZA-2'-deoxycytidine-5'-monophosphate and its 5'-triphosphate with deoxycytidylate deaminase. Mol. Pharmacol. (1984) 25 436-440.
41. Van Rompay A.R., Johansson M., Karlsson A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol. Ther. (2000) 87 189-198.
42. De Clercq E., Balzarini J., Descamps J. et al. Antiviral, antimetabolic, and cytotoxic activities of 5-substituted 2'-deoxycytidines. Mol. Pharmacol. (1982) 21 217-223.
43. Ellims P.H., Kao A.Y., Chabner B.A. Deoxycytidylate deaminase. Purification and some properties of the enzyme isolated from human spleen. J. Biol. Chem. (1981) 256 6335-6340.
44. Mancini W.R., Cheng Y.C. Human deoxycytidylate deaminase. Substrate and regulator specificities and their chemotherapeutic implications. Mol. Pharmacol. (1983) 23 159-164.
45. Liou J.Y., Krishnan P., Hsieh C.C., Dutschman G.E., Cheng Y.C. Assessment of the effect of phosphorylated metabolites of anti-human immunodeficiency virus and anti-hepatitis B virus pyrimidine analogs on the behavior of human deoxycytidylate deaminase. Mol. Pharmacol. (2003) 63 105-110.
46. Ellims P.H., Kao A.Y., Chabner B.A. Kinetic behaviour and allosteric regulation of human deoxycytidylate deaminase derived from leukemic cells. Mol. Cell. Biochem. (1983) 57 185-190.
47. Scarano E., Geraci G., Rossi M. Deoxycytidylate aminohydrolase. II. Kinetic properties. The activatory effect of deoxycytidine triphosphate and the inhibitory effect of deoxythymidine triphosphate. Biochemistry (1967) 6 192-201.
48. Momparler R.L., Rossi M., Bouchard J. et al. 5-AZA-2'-deoxycytidine synergistic action with thymidine on leukemic cells and interaction of 5-AZA-dCMP with dCMP deaminase. Adv. Exp. Med. Biol. (1986) 195(Pt B) 157-163.
49. Xu Y.Z., Plunkett W. Modulation of deoxycytidylate deaminase in intact human leukemia cells: action of 2', 2'-difluorodeoxycytidine. Biochem. Pharmacol. (1992) 44 1819-1827.
50. Gilbert J.A., Salavaggione O.E., Ji Y. et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin. Cancer Res. (2006) 12 1794-1803.
51. Ikenaka K., Fukushima M., Nakamura H., Okamoto M., Shirasaka T., Fujii S. Metabolism of pyrimidine nucleotides in various tissues and tumor cells from rodents. Gann (1981) 72 590-597.
52. Maehara Y., Nakamura H., Nakane Y. et al. Activities of various enzymes of pyrimidine nucleotide and DNA syntheses in normal and neoplastic human tissues. Gann (1982) 73 289-298.
53. Giusti G., Mangoni C., De Petrocellis B., Scarano E. Deoxycytidylate deaminase and deoxycytidine deaminase in normal and neoplastic human tissues. Enzymol. Biol. Clin. (Basel) (1970) 11 375-383.
54. Vincent B.R., Buttin G. Studies on 1-beta-D-arabinofuranosyl cytosine-resistant mutants of Chinese hamster fibroblasts: III. Joint resistance to arabinofuranosyl cytosine and to excess thymidine--a semidominant manifestation of deoxycytidine triphosphate pool expansion. Somatic. Cell Genet. (1979) 5 67-82.
55. Ellims P.H., Medley G. Deoxycytidylate deaminase activity in lymphoproliferative disorders. Leuk. Res. (1984) 8 123-128.
56. Danenberg P.V., Malli H., Swenson S. Thymidylate synthase inhibitors. Semin. Oncol. (1999) 26 621-631.
57. Langenbach R.J., Danenberg P.V., Heidelberger C. Thymidylate synthetase: mechanism of inhibition by 5-fluoro-2'-deoxyuridylate. Biochem. Biophys. Res. Commun. (1972) 48 1565-1571.
58. Weckbecker G. Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators. Pharmacol. Ther. (1991) 50 367-424.
59. Ziemkowski P., Felczak K., Poznanski J. et al. Interactions of 2'-fluoro-substituted dUMP analogues with thymidylate synthase. Biochem. Biophys. Res. Commun. (2007) 362 37-43.
60. Ruiz van Haperen V.W., Veerman G., Smid K., Pinedo H.M., Peters G.J. Gemcitabine inhibits thymidylate synthase (TS) activity in solid tumour cell lines. Proceedings of the american association for cancer research 36[354]. 1995.
61. FitzGerald G.B., Ratliff J., Wick M.M. Inhibition of thymidylate synthase in intact L1210 cells by ara-C, daunomycin, hydroxyurea and 3, 4-dihydroxybenzylamine. Anticancer Drug Des. (1987) 1 281-289.
62. Muller W.E., Yamazaki Z.I., Sogtrop H.H., Zahn R.K. Action of 1- -D-arabinofuranosylcytosine on mammalian tumor cells. 2. Inhibition of mammalian and oncogenic viral polymerases. Eur. J. Cancer (1972) 8 421-428.
63. Ono K., Ohashi A., Ogasawara M. et al. Inhibition of deoxyribonucleic acid polymerases from murine cells and oncornavirus by 5-alkylated derivatives of 1-beta-D-arabinofuranosyluracil 5'-triphosphate: substituent effects on inhibitory action. Biochemistry (1981) 20 5088-5093.
64. Gandhi V., Chapman A., Huang P., Plunkett W. Sequence-specific inhibition of DNA polymerase á by 5'-triphosphates of arabinosylcytosine and arabinosyluracil. Proc Am Assoc Cancer Res (1993) 34 349.
65. Ruiz van Haperen V.W., Veerman G., Vermorken J.B., Peters G.J. 2', 2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol. (1993) 46 762-766.
66. Kaysen J., Spriggs D., Kufe D. Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells. Cancer Res. (1986) 46 4534-4538.
67. Danenberg P.V., Heidelberger C., Mulkins M.A., Peterson A.R. The incorporation of 5-fluoro-2'-deoxyuridine into DNA of mammalian tumor cells. Biochem. Biophys. Res. Commun. (1981) 102 654-658.
68. Tanaka M., Yoshida S., Saneyoshi M., Yamaguchi T. Utilization of 5-fluoro-2'-deoxyuridine triphosphate and 5-fluoro-2'-deoxycytidine triphosphate in DNA synthesis by DNA polymerases alpha and beta from calf thymus. Cancer Res. (1981) 41 4132-4135.
69. Pauwels B., Korst A.E., Lambrechts H.A. et al. The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro. Cancer Chemother. Pharmacol. (2006) 58 219-228.
70. Oki Y., Aoki E., Issa J.P. Decitabine--bedside to bench. Crit. Rev. Oncol. Hematol. (2007) 61 140-152.
71. Plunkett W., Liliemark J.O., Estey E., Keating M.J. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin. Oncol. (1987) 14 159-166.
72. Veltkamp S.A., Beijnen J.H., Schellens J.H. Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy. Oncologist (2008) 13 261-276.
73. Grunewald R., Kantarjian H., Keating M.J., Abbruzzese J.L., Tarassoff P., Plunkett W. Pharmacologically Directed Design of the Dose Rate and Schedule of 2', 2'-Difluorodeoxycytidine (Gemcitabine) Administration in Leukemia. Cancer Res. (1990) 50 6823-6826.
74. Kreis W., Chan K., Budman D.R. et al. Effect of tetrahydrouridine on the clinical pharmacology of 1-beta-D-arabinofuranosylcytosine when both drugs are coinfused over three hours. Cancer Res. (1988) 48 1337-1342.
75. Beumer J.H., Eiseman J.L., Parise R.A., Joseph E., Covey J.M., Egorin M.J. Modulation of gemcitabine (2', 2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3, 4, 5, 6-tetrahydrouridine. Clin. Cancer Res. (2008) 14 3529-3535.
76. Beumer J.H., Parise R.A., Newman E.M. et al. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother. Pharmacol. (2008) 62 363-368.
77. Laliberte J., Marquez V.E., Momparler R.L. Potent inhibitors for the deamination of cytosine arabinoside and 5-aza-2'-deoxycytidine by human cytidine deaminase. Cancer Chemother. Pharmacol. (1992) 30 7-11.
78. Lemaire M., Momparler L.F., Raynal N.J., Bernstein M.L., Momparler R.L. Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine. Cancer Chemother. Pharmacol. (2008) 63 411-416.
79. Lemaire M., Momparler L.F., Bernstein M.L., Marquez V.E., Momparler R.L. Enhancement of antineoplastic action of 5-aza-2'-deoxycytidine by zebularine on L1210 leukemia. Anticancer Drugs (2005) 16 301-308.
80. Hamada A., Kawaguchi T., Nakano M. Clinical pharmacokinetics of cytarabine formulations. Clin. Pharmacokinet. (2002) 41 705-718.
81. Castelli F., Sarpietro M.G., Ceruti M., Rocco F., Cattel L. Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry. Mol. Pharm. (2006) 3 737-744.
82. Galmarini C.M., Myhren F., Sandvold M.L. CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines. Br. J. Haematol. (2009) 144 273-275.
83. Khoury H., Deroussent A., Reddy L.H., Couvreur P., Vassal G., Paci A. Simultaneous determination of gemcitabine and gemcitabine-squalene by liquid chromatography-tandem mass spectrometry in human plasma. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. (2007) 858 71-78.
84. Landowski C.P., Lorenzi P.L., Song X., Amidon G.L. Nucleoside ester prodrug substrate specificity of liver carboxylesterase. J. Pharmacol. Exp. Ther. (2006) 316 572-580.
85. Pasut G., Canal F., Dalla V.L., Arpicco S., Veronese F.M., Schiavon O. Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J. Control Release (2008) 127 239-248.
86. Wu W., Sigmond J., Peters G.J., Borch R.F. Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. J. Med. Chem. (2007) 50 3743-3746.
87. Tobias S.C., Borch R.F. Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol. Pharm. (2004) 1 112-116.
88. Yoo C.B., Jeong S., Egger G. et al. Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. (2007) 67 6400-6408.
89. Naesens L., Andrei G., Votruba I. et al. Intracellular metabolism of the new antiviral compound 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine. Biochem. Pharmacol. (2008) 76 997-1005.
90. Ludwig P.S., Schwendener R.A., Schott H. Synthesis and anticancer activities of amphiphilic 5-fluoro-2'-deoxyuridylic acid prodrugs. Eur. J. Med. Chem. (2005) 40 494-504.
91. Galmarini C.M., Warren G., Kohli E., Zeman A., Mitin A., Vinogradov S.V. Polymeric nanogels containing the triphosphate form of cytotoxic nucleoside analogues show antitumor activity against breast and colorectal cancer cell lines. Mol. Cancer Ther. (2008) 7 3373-3380.